Avitia, a Montreal, Canada-based AI company providing end-to-end testing solutions to rapidly identify cancer mutations and applicable treatments, raised $5M in seed funding.
PacBridge Capital Partners made the investment.
The company intends to use the funds to expand into new markets and enhance its platform’s capabilities.
Led by CEO James Lumsdaine, Avitia delivers advanced NGS-molecular testing solutions directly to laboratories via the company’s AI/ML platform. The company’s modular precision medicine technology equips cancer centers with NGS capabilities and network-wide insights. With its automated platform, any lab can conduct liquid biopsy assays on-site — reducing testing time and cost while improving patient outcomes.
Avitia’s technology is currently used by partners in Canada, the United States, and Southeast Asia.
FinSMEs
27/02/2025